This suggests that persistent inflammation that develops into cachexia or inappropriately increases PD-L1 expression may attenuate the immune response by PD-1/PD-L1 inhibition, even when PD-L1 is highly expressed on tumor cells. The gene discussed is CD274; the disease is Cachexia.